Paolo T. Ambrosino

Benevento, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study.

Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study.

Journal: Annals of neurology

Published: October 17, 2024

Pharmacological approaches in drug-resistant pediatric epilepsies caused by pathogenic variants in potassium channel genes.

Pharmacological approaches in drug-resistant pediatric epilepsies caused by pathogenic variants in potassium channel genes.

Journal: Frontiers in cellular neuroscience

Published: October 16, 2024

In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel.

In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel.

Journal: Journal of medicinal chemistry

Published: May 23, 2024

Case report: Marked electroclinical improvement by fluoxetine treatment in a patient with KCNT1-related drug-resistant focal epilepsy.

Case report: Marked electroclinical improvement by fluoxetine treatment in a patient with KCNT1-related drug-resistant focal epilepsy.

Journal: Frontiers in cellular neuroscience

Published: January 09, 2024

Resistance to erythropoiesis stimulating agents in a dialysis patient after kidney graft failure.

Resistance to erythropoiesis stimulating agents in a dialysis patient after kidney graft failure.

Journal: Journal of nephrology

Published: September 22, 2023

De novo variants in KCNA3 cause developmental and epileptic encephalopathy.

De novo variants in KCNA3 cause developmental and epileptic encephalopathy.

Journal: Annals of neurology

Published: January 16, 2023

A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetine.

A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetine.

Journal: Epilepsia

Published: January 05, 2023

KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties.

KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties.

Journal: Annals of neurology

Published: August 02, 2022

COVID-19 epidemic spread and green areas Italy and Spain between 2020 and 2021: An observational multi-country retrospective study.

COVID-19 epidemic spread and green areas Italy and Spain between 2020 and 2021: An observational multi-country retrospective study.

Journal: Environmental research

Published: April 08, 2022

Gain of function due to increased opening probability by two KCNQ5 pore variants causing developmental and epileptic encephalopathy.

Gain of function due to increased opening probability by two KCNQ5 pore variants causing developmental and epileptic encephalopathy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 04, 2022

Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes.

Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes.

Journal: Frontiers in pharmacology

Published: February 09, 2022

KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism.

KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism.

Journal: EBioMedicine

Published: January 22, 2022

Showing 1-12 of 47

Last Updated: 09/26/2026